Alicia Fivecoat was 62 and Whitney was not yet 1 when they were diagnosed. When Alicia Fivecoat, a mom of two, felt a golf ...

Subsequent leukemia was associated with high cumulative doses of epipodophyllotoxins, older age at initial cancer diagnosis, and receipt of hematopoietic stem cell transplant.

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment. “We are excited to announce the initiation of ...

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

Granted FDA Rare Pediatric Disease Designation (RPDD): The FDA granted ... In Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia After Prior Venetoclax ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...